A Multicentre, Randomized, Double Blind, Double-Dummy, Three-period, Six-Sequence, Crossover, Active and Placebo Controlled, Single Dose Pharmacodynamic Study to Evaluate Therapeutic Equivalence of Test Formulation Tiotropium Bromide Inhalation Powder to Reference Formulation SPIRIVA® HANDIHALER® (Tiotropium bromide inhalation powder) in participants with Chronic Obstructive Pulmonary Disease.

Phargentis SA0 个研究点目标入组 296 人开始时间: 待定最近更新: 2023年11月13日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 296

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•1.Participant must sign an ICF indicating that he or she understands the purpose of, and procedures required for the study in this protocol and is willing to participate in the study.
•2. Male or female participant must be of = 40 years of age, at the time of signing the informed consent.
•Participants who are medically stable on the basis of physical examination, medical history, and vital signs, chest X-ray and 12-lead ECG performed at screening. Any abnormalities, must be consistent with the underlying illness in the study population and this determination must be recorded in the participants source documents and initialed by the investigator.
•Participants with documented Diagnosis of COPD, as defined by American Thoracic Society (ATS) [GOLD criteria] at screening.
•6. Pre-bronchodilator FEV1 = 35% and = 80% of predicted at screening and visits 3-5. At visits 3-5, the average of the quality FEV1 measurements will be used to determine the baseline FEV1, and must be = 35% and = 80% of predicted normal value and may not vary by more than ± 20% from the qualifying screening visit FEV1 value.
•Participant must demonstrate at screening, post-bronchodilator FEV1=80% of predicted.
•8. Participant must demonstrate at screening, post-bronchodilator FEV1/FVC ratio =0.70.
•Participant demonstrate = 15 % reversibility of FEV1 within 45 minutes following 4 inhalations of ipratropium bromide HFA inhalation aerosol (84 mcg) at Screening.
•10.Participants must administer at least 70% doses of placebo during the run-in period.
•Participants who are Current or former cigarette smokers with a history of cigarette smoking of =10 pack-years at Screening (visit 1) Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1
•12.A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
•a. Is not a woman of childbearing potential (WOCBP) b. Is a WOCBP and using an acceptable contraceptive method as
•described in Appendix 10.4 during the intervention period and at a
•minimum 15 days until after the last dose of study intervention. The
•investigator should evaluate the effectiveness of the contraceptive
•method in relationship to the first dose of study intervention. c. A WOCBP must have a negative highly sensitive serum pregnancy
•test at screening and negative urine pregnancy test prior to dosing of
•Participants willing and able to adhere to the lifestyle restrictions specified in this protocol.
•14.Participants able to understand and comply with the study procedures, in the opinion of the investigator.

排除标准

•Any potential participant who meets any of the following criteria will be excluded from participating in the study:
•1. Participants with history of liver or renal insufficiency (estimated creatinine clearance below 60 mL/min); significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
•2. Known respiratory disorder other than COPD, including but not limited to the following: active tuberculosis, lung cancer, alpha-1-antitrypsin deficiency, cystic fibrosis, significant asthma, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema or interstitial lung disease.
•3. Participants with a1-antitrypsin deficiency as the underlying cause of COPD at screening.
•4. Participants with history of paradoxical bronchospasm, narrow-angle glaucoma, prostatic hypertrophy, or bladder neck obstruction, which, in the investigator’s opinion, would contraindicate the use of an anticholinergic agent.
•5. Participants with history of allergy or hypersensitivity to anticholinergic/muscarinic receptor antagonist agent, beta-2 adrenergic agonists, lactose/milk proteins or specific intolerance to aerosolized tiotropium or ipratropium bromide-containing products or known hypersensitivity to any of the proposed ingredients or components of the delivery system.
•6. Participants with use of oral/parenteral corticosteroids or antibiotics for COPD within 6 weeks or depot corticosteroids within 3 months prior to screening.
•7. Participants with hospitalization for COPD or pneumonia within 12 weeks prior to study screening and randomization.
•8. Participants with treatment for COPD exacerbation within 12 weeks prior to study screening and randomization. 9. Participants with acute (viral or bacterial) upper or lower respiratory tract infection include sinusitis, rhinitis, pharyngitis, urinary tract infection or illness within 6 weeks prior to screening.
•10. Patients with sign and/or symptoms suggestive of COVID 19 infection at the time of screening.
•11. Participants with lung volume reduction surgery within the previous 12 months of randomization.
•12. Participants with chronic oxygen uses for >12 hours/day.
•13. Participants with evidence or history of other clinically significant disease or abnormal (such as congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, stroke, glaucoma or cardiac dysrhythmia) condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
•14. Participants had major surgery, (e.g., requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study.
•15. Participants with history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at Screening.
•16. Participants with history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at Screening. 17. Participant is unable to stop the medications at the defined times prior to scree

研究者

发起方

Phargentis SA

相似试验

进行中（未招募）

不适用

A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects with Malignancies

EUCTR2007-000558-30-BESosei R&D Ltd150

进行中（未招募）

不适用

A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.

EUCTR2004-005032-35-HUAlizyme Therapeutics Limited890

进行中（未招募）

不适用

EUCTR2007-000558-30-GBSosei R&D Ltd150

进行中（未招募）

不适用

A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.

EUCTR2004-005032-35-DKAlizyme Therapeutics Limited890

招募中

3 期

A study to check effectiveness of Dimethyl Fumarate Gastro-Resistant Hard Capsule in patients with Moderate to Severe Chronic Plaque Psoriasis.

CTRI/2020/12/029611Alvogen Malta OutLicensing Ltd